Overview

Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic

Status:
Recruiting

Trial end date:
2024-05-31

Target enrollment:
0

Participant gender:
All

Summary

Acute stroke afflicts nearly 700,000 patients in the US and is the number 3 cause of death. Only 2-9% of this large number is treated with t-PA if they arrive within 4.5 hours. An equally small percentage of patients with large vessel occlusion undergo thrombectomy. The thrombectomy patients may or may not receive t-PA. Some of these patients rarely receive intravenous GPIIB/IIIa inhibitors. Many lines of evidence suggest that GP IIb/IIIa inhibitors, a class of FDA approved potent platelet inhibitors that have been used extensively along with heparin for acute coronary syndromes (heart attacks) and unstable angina (chest pain), may be safe enough to give in these circumstances.

Phase:

Phase 1/Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Baylor College of Medicine

Treatments:

Eptifibatide
Fibrinolytic Agents

Criteria

Inclusion Criteria:

1. Subjects are 18 years or older

2. Anterior Circulation stroke within the last six hours

3. Posterior Circulation stroke within the last 12 hours

Exclusion Criteria:

1. Initial CT of the head suggests stroke like symptoms are not due to an ischemic stroke
but a result of hemorrhage or tumor

2. Platelet count below 100,000

3. PTT greater than 75 while on treatment with heparin

4. INR greater than 2.5 while on treatment with warfarin

5. ACT>250

6. Have clinical signs and symptoms of liver failure or elevations in AST, and ALT > 3
times the normal values.

7. Creatinine greater than 2

8. Treatment team considers the patient to be at increased risk of intra-cerebral
hemorrhages or systemic bleeding

9. Pre-morbid modified Rankin score >2 suggesting a functionally dependent patient.